Asian Journal of Dermatology1996-3424xxxx-xxxxAsian Network for Scientific Information10.3923/ajd.2017.1.6GhanemBothaina Mahrous SallamManar El-Sayed El-HawaryAmira Kamal EL-TantawyDina AhmedRehab-Allah DarwishMohamed 1201791Background and Objective: Little is known about cytokine expression in skin of vitiligo patients. Studies of serum cytokine concentrations in vitiligo are few and results are often contradictory. This study aimed to examine the degree of expression of transforming growth factor (TGF-β1) in both the serum and the lesional skin of vitiligo patients. Materials and Methods: In this study, 38 patients with non-segmental vitiligo and 40 age and sex-matched controls were recruited. The TGF-β1 1evels were detected in serum using ELISA and in lesional specimens of cases and in controls by immunohistochemistry. The statistical analysis of the data was performed using independent T test, the Mann-Whitney U-test, Kruskal-Wallis test, X2-test, exact test and Spearman correlation test . Results: The levels of serum TGF-β1 in patients with vitiligo showed no significant difference in comparison to controls (p = 0.523). Positive epidermal staining for TGF-β1 was detected in 10/24 (41.7%) of patients. The staining was mainly basal and suprabasal with no significant difference from controls. No relation was found between levels of TGF-β1 and disease extent or activity. Conclusion: Normal serum levels and lesional expression of TGF-β1 in this investigation do not support a role related to impaired levels of this cytokine in melanocyte cytotoxicity. Further studies about the TGF-β1 mediated signaling pathway in vitiligo is required to establish the role of TGF-β1 in the pathogenesis of vitiligo.]]>Kyriakis, K.P., I. Palamaras, E. Tsele, C. Michailides and S. Terzoudi,200948328329Zhang, Z., S.X. Xu, F.Y. Zhang, X.Y. Yin and S. Yang et al.,2009301167173Taieb, A. and M. Picardo,2007202735Le Poole, I.C. and R.M. Luiten,200810227243Van den Boorn, J.G., D. Konijnenberg, T.A. Dellemijn, J.W. van der Veen and J.D. Bos et al.,200912922202232Oiso, N., T. Suzuki, K. Fukai, I. Katayama and A. Kawada,20112011Li, M.O. and R.A. Flavell,2008134392404Vila, J., J.D. Isaacs and A.E. Anderson,200916274279Sanjabi, S., L.A. Zenewicz, M. Kamanaka and R.A. Flavell,20099447453Chodorowska, G., J. Bartosinska, M. Dabrowska-Czlonka, B. Wawrzycki and M. Juszkiewicz-Borowiec,20082514Tu, C.X., W.W. Jin, M. Lin, Z.H. Wang and M.Q. Man,2011+CD25+ T cells from patients with non-segmental vitiligo.]]>303685689Zhou, L., Y.L. Shi, K. Li, I. Hamzavi and T.W. Gao et al.,201528324329Abdou, A.G., A.H. Maraee, A.M. Al-Bara and W.M. Diab,2011338491SPSS.,2007Afzali, B., G. Lombardi, R.I. Lechler and G.M. Lord,20071483246Eby, J.M., H.K. Kang, J. Klarquist, S. Chatterjee and J.A. Mosenson et al.,20142710751085Singh, R.P., A. La Cava, M. Wong, F. Ebling and B.H. Hahn,2007+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression.]]>17876497657Nishimura, E.K., M. Suzuki, V. Igras, J. Du and S. Lonning et al.,20106130140Basak, P.Y., A.K. Adiloglu, A.M. Ceyhan, T. Tas and V.B. Akkaya,200960256260Hegab, D.S. and M.A.S. Attia,20152015Richetta, A., S. D’Epiro, M. Salvi, M. Campoli and S. Giancristoforo et al.,201323154159Dwivedi, M., N.C. Laddha, P. Arora, Y.S. Marfatia and R. Begum,2013+/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo.]]>26586591Klarquist, J., C.J. Denman, C. Hernandez, D.J. Wainwright and F.M. Strickland et al.,201023276286Tembhre, M.K., V.K. Sharma, A. Sharma, P. Chattopadhyay and S. Gupta,20134242732Han, G., C.A. Williams, K. Salter, P.J. Garl, A.G. Li and X.J. Wang,2010130371377Han, G., S.L. Lu, A.G. Li, W. He, C.L. Corless, M. Kulesz-Martin and X.J. Wang,200511517141723Zaher, H., O.G. Shaker, M.H.M. El-Komy, A. El-Tawdi, M. Fawzi and D. Kadry,200923406409Cutroneo, K.R.,200715S54S60Moretti, S., A. Spallanzani, L. Amato, G. Hautmann, I. Gallerani, M. Fabiani and P. Fabbri,2002158792